RE: Placing and the two-way facing of rampers26 May 2026 13:31
As previously stated by the company: CRISM Therapeutics is fully funded to initiate the initial 12-patient, dose-escalation portion of its Phase 2 clinical trial for its ChemoSeed cancer treatment. The funding and setup costs are being covered by proceeds from a £1,000,000 share placing and a separate £100,000 retail offer. There has obviously been some slippage as the first patient was due to be treated in Q1 hence one of the reasons for today’s announcements.